Market Trends of Photopheresis Products Industry
Chronic Graft Versus Host Disease (GvHD) is Expected to Hold a Significant Market Share in the Market Studied.
- Chronic Graft-versus-host disease (GvHD) is a systemic disorder that happens when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. It is a common complication after an allogeneic hematopoietic stem cell transplant (HCT). In GvHD, the recipient's body is attacked by the donated bone marrow or peripheral blood stem cells as they perceive it as foreign.
- Extracorporeal photopheresis (ECP) remains one of the subsequent therapeutic choices in the treatment of GvHD, thereby driving market growth. According to the study published in Medicine in November 2022, with an overall response rate ranging from 31% to 93% and the maximum efficacy reported for individuals with skin involvement, ECP's effectiveness in treating cGVHD is well-documented.
- It should be noted that for a clear visual result, prolonged ECP is typically required. In addition, according to the study published in the American Society for Transplantation and Cellular Therapy in November 2022, ECP is an effective immunomodulatory therapy with mild adverse events in GvHD. Such advantages and effectiveness of photopheresis in GvHD are expected to increase adoption, driving the segment growth.
- In addition, rising initiatives from the national governments for the implementation of ECP for GvHD are expected to bolster segment growth over the forecast period. For instance, in March 2022, the Government of Australia passed a regulation for initial ECP treatment, and continuing ECP treatment will be introduced for patients with GvHD following allogeneic hematopoietic stem cell transplantation. Such initiatives will lead to increased adoption of ECP in GvHD, driving segment growth.
- Therefore, the rising initiatives from the government and the importance of photopheresis in GvHD are the factors expected to drive the segment growth.
Understand The Key Trends Shaping This Market
Download PDF
North America is Holds a Significant Share and Expected to do the Same in the Forecast Period
- The factors driving the market in North America include rising organ donations, a strong foothold and rising initiatives of the key market players, and developed healthcare infrastructure, among others.
- According to the United States Department of Health and Human Services, in March 2022, more than 40,000 transplants took place in 2021, that include 24,670 kidney and 9,236 liver transplantations, among others.
- In addition, according to the Canadian Institute of Health Information, in June 2022, a total of 2,782 organ transplants were performed in Canada in 2021, including 78% deceased donor organs and 21% living donor organs. Such organ transplantation will drive market growth in the region due to the increased adoption of photopheresis products to overcome organ transplant rejection.
- Furthermore, the rising initiatives from the key market players are also expected to drive market growth in the region. For instance, in July 2021, Terumo Blood and Cell Technologies launched a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside.
- Terumo Blood and Cell Technologies is a medical technology company that specializes in a portfolio of products, software, and services for blood collection, therapeutic apheresis, and cellular technologies. Such an initiative will lead to increased adoption of photopheresis products in blood collection and processing, driving market growth.
- Moreover, the presence of blood processing centers and advanced apheresis are also some of the main factors ensuring the dominance of the region. Therefore, owing to the factors such as rising organ transplantation and rising initiatives from the key market players are expected to drive market growth in the region.
Get Analysis on Important Geographic Markets
Download PDF
